Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + chemotherapy in first-line extensive-stage small cell lung cancer
2020-005230-15Phase 2Active
- Sponsor
- Fundación GECP
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab and lenvatinib in small cell lung cancer (SCLC), sponsored by Fundación GECP. Primary endpoints: Safety and tolerability of lenvatinib 8 mg in combination with pembrolizumab plus carboplatin and etoposide (Part 1) and Preliminary efficacy of pembrolizumab + lenvatinib + carboplatin + etoposide (Part 1). Started May 2022; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-005230-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005230-15.